Brief: Rubius Therapeutics Plans To File Investigational New Drug Application For Rtx-240 By Early 2020
02/04/2019 13:41
April 2 (Reuters) - Rubius Therapeutics Inc RUBY.O :
* RUBIUS THERAPEUTICS ANNOUNCES EXTENSIVE PRECLINICAL DATA
FOR
THREE RED CELL THERAPEUTIC ONCOLOGY PROGRAMS AT THE 2019
AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING
* RUBIUS THERAPEUTICS -RTX-240, RTX-224 EACH POTENTLY
STIMULATED
DIFFERENT COMPONENTS OF IMMUNE SYSTEM & DEMONSTRATE POTENTIALLY
WIDE THERAPEUTIC WINDOW
* RUBIUS THERAPEUTICS-RTX-240 AND RTX-224 SHOWED IMPRESSIVE
ANTITUMOR ACTIVITY,NO OBSERVED TOXICITY COMPARED TO AGONISTS
ANTIBODIES/ RECOMBINANT CYTOKINES
* RUBIUS THERAPEUTICS - RTX-224 IN COMBINATION WITH
ANTI-PD-1
ANTIBODY SHOWED SUBSTANTIAL TUMOR SHRINKAGE IN
DIFFICULT-TO-TREAT MC38 COLON CANCER MODEL
* RUBIUS THERAPEUTICS INC - PLANS TO FILE INVESTIGATIONAL
NEW DRUG
APPLICATION FOR RTX-240 BY EARLY 2020
Source text for Eikon: ID:nGNX3xGmWV
Further company coverage: RUBY.O
((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))
Recent news on Rubius Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Apple, TCR2 Therapeutics, Silvergate Capital
Brief: Rubius Therapeutics Inc - Nasdaq Notified Co That Trading In Co's Stock Will Be Suspended Upon Opening Of Business On March 7, 2023
Brief: Rubius Therapeutics Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Rubius Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Baidu, Boeing, Microsoft